EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections

Natalie A Mackow, Wanying Shao, Lizhao Ge, Lauren Komarow, Jianping Jiang iD, Angelique Boutzoukas iD, Liang Chen iD, Julia Garcia-Diaz, Erica S Herc, Yohei Doi iD, Cesar A Arias, Owen Albin iD und 20 weitere

Clinical Infectious Diseases · 23.07.2026 · 83 (1) · e27-e37

DOI: 10.1093/cid/ciag160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 06.03.2026. Verfasst von Natalie A Mackow und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Escherichia coli, Escherichia coli Infections, Carbapenems, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases.

Methods

A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset.

Results

This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups.

Conclusions

Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliEscherichia coli InfectionsCarbapenemsAnti-Bacterial AgentsBacteremiaHumansProspective StudiesCeftriaxoneFemaleMaleAgedMiddle AgedThird Generation CephalosporinsAged, 80 and overMicrobial Sensitivity TestsUnited States

Stichwörter der Autor:innen

E. coliST131bacteremiacarbapenemsceftriaxone resistance

Substanzen

CarbapenemsAnti-Bacterial AgentsCeftriaxoneThird Generation Cephalosporins

Autor:innen und Institutionen

  • Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Biostatistics Center, George Washington University, Rockville, Maryland, USA.
  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley New Jersey, USA.
  • Department of Pediatrics, Duke University, Durham, North Carolina, USA.
  • Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
  • School of Pharmacy and Pharmaceutical Sciences, SUNY Buffalo, Buffalo, NewYork, USA.

ORCID-Profile: Jianping Jiang, Angelique Boutzoukas, Liang Chen, Yohei Doi, Owen Albin, Elie Saade, Loren G Miller, Jesse T Jacob, Michael J Satlin, Martin Krsak, W Charles Huskins, Samuel A Shelburne, Carol Hill, Kevin Alby, Jacob M Sadler, Bravada M Hill, Robin Patel, Vance G Fowler, Pranita D Tamma, David van Duin

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Merck
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Mackow, N. A., Shao, W., Ge, L., Komarow, L., Jiang, J., Boutzoukas, A., Chen, L., Garcia-Diaz, J., Herc, E. S., Doi, Y., Arias, C. A., Albin, O., Saade, E., Miller, L. G., Jacob, J. T., Satlin, M. J., Krsak, M., Huskins, W. C., Dhar, S., …, & Antibacterial Resistance Leadership Group (2026). Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections. Clinical Infectious Diseases, 83(1), e27-e37. https://doi.org/10.1093/cid/ciag160

Vancouver

Mackow NA, Shao W, Ge L, Komarow L, Jiang J, Boutzoukas A, et al. Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections. Clinical Infectious Diseases. 2026;83(1):e27-e37. doi:10.1093/cid/ciag160

BibTeX
@article{Mackow2026,
  author = {Mackow, Natalie A and Shao, Wanying and Ge, Lizhao and Komarow, Lauren and Jiang, Jianping and Boutzoukas, Angelique and Chen, Liang and Garcia-Diaz, Julia and Herc, Erica S and Doi, Yohei and Arias, Cesar A and Albin, Owen and Saade, Elie and Miller, Loren G and Jacob, Jesse T and Satlin, Michael J and Krsak, Martin and Huskins, W Charles and Dhar, Sorabh and Shelburne, Samuel A and Hill, Carol and Alby, Kevin and Sadler, Jacob M and Hill, Bravada M and Greenwood-Quaintance, Kerryl E and Schmidt-Malan, Suzannah M and Patel, Robin and Fowler, Vance G and Tamma, Pranita D and Kreiswirth, Barry N and van Duin, David and Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group},
  title = {Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {83},
  number = {1},
  pages = {e27--e37},
  doi = {10.1093/cid/ciag160}
}
Kostenlos starten →